Abstract: Current strategies for the treatment of human immunodeficiency virus (HIV) infection are based on cocktails of drugs that target the viral entry step and the enzymes reverse transcriptase or protease. At present, the clinical benefit of this combination therapy for HIV-infected patients is considerable, although it is not clear how long this effect will last taking into account the emergence of multiple drug-resistant viral strains. Addition of new anti-HIV drugs targeting additional steps of the viral replication cycle may increase the potency of inhibition and prevent significant resistance development. During HIV replication, integration of the viral genome into the cellular chromosome is an essential step catalyzed by the viral integrase. Although HIV integrase is an attractive target for antiviral therapy and the focus of intensive research, to date only two classes of compounds that selectively inhibit HIV integration have been identified, namely the diketo acids and the pyranodipyrimidines. In this review we address the question why it has proven so difficult to find potent and selective integrase inhibitors; we point to potential pitfalls in defining an inhibitor as an authentic integrase inhibitor and we propose new strategies and new technologies for the discovery of genuine HIV integration inhibitors. For the diketo acids and the pyranodipyrimidines we will discuss in detail the antiviral activity, the molecular mechanism of anti-HIV action, the in vitro HIV resistance development and the clinical perspectives.
INTRODUCTION
The Acquired Immune Deficiency Syndrome (AIDS) is caused by the human immunodeficiency virus (HIV). Stateof-the-art therapy of patients infected with HIV is based on combination cocktails with potent antivirals targeting viral entry, reverse transcriptase and protease [20, 21] . Highly active antiretroviral therapy (HAART) is of great benefit for most patients, although long-term therapeutic success may be jeopardised by the emergence of virus strains resistant to currently used drugs. Therefore, a continuous effort to develop new antivirals is warranted. The novel antivirals are preferentially directed against new viral or cellular targets to reduce the risk for cross-resistance.
The integration of retro-transcribed viral DNA into the host chromosome is an essential step in the replication cycle of retroviruses. After integration the proviral DNA is replicated and genetically transmitted as part of the cellular genome. Thus, integration defines a point of no return in the life cycle of HIV. The integrase of HIV is an attractive target for selective antiviral therapy since there is no known functional homologue in human cells [50] . The enzyme of 32 kDa is encoded by the 3' part of the pol gene. HIV-1 integration encompasses a series of molecular events that follows the completion of reverse transcription in the cytoplasm of the infected cell and that ends with the initiation of transcription from the inserted proviral DNA. An overview of these events during retroviral DNA integration is shown in (Fig. 1) [6] . The DNA product *Address correspondence to this author at the Rega Institute for Medical Research, K.U. Leuven, Minderbroedersstraat 10, B-3000 Leuven, Flanders, Belgium; Tel: 32-16-332-183; Fax: 32-16-332-131; E-mail: zeger.debyser@ med.kuleuven.ac.be formed after reverse transcription is a double-stranded linear DNA with Long Terminal Repeat (LTR) sequences at each end. This molecule is the substrate for HIV-1 integrase that will catalyze and facilitate several steps that finally result in the insertion of the viral DNA into the host cell's chromosome. In the cytoplasm, reactions take place in a subviral particle first referred to as reverse transcription complex, later as pre-integration complex (PIC). In the PIC integrase removes the terminal GT dinucleotides from each LTR 3' end. This site-specific endonucleolytic activity is referred to as the '3'-processing' reaction. After the PIC is transported through the nuclear pore, the viral DNA is joined to the cellular DNA. This 'strand-transfer' step includes a staggered cleavage of host DNA, and a ligation of the processed 3'-OH ends of the viral DNA into the host DNA. 3'-ends of the target DNA remain unjoined after the strand transfer. The integration reaction is completed by the removal of the two unpaired nucleotides at the 5'-end of the viral DNA and the repair of the single stranded gaps created between the viral and target DNA. This step is likely carried out by cellular DNA repair enzymes [92] , although a possible role of RT and IN [17] has been proposed. Staggered strand transfer and gap repair result in the duplication of host cell sequences immediately flanking the inserted proviral DNA.
A decade of HIV integrase research has not resulted in the development of an integrase inhibitor approved for clinical use. In our manuscript we will indicate new antiviral targets related to retroviral integration that are amenable to drug development. We will describe the pitfalls of currently used integrase assays and propose solutions and technologies to circumvent misidentification of integrase inhibitors. Furthermore, we will describe the two classes of integrase inhibitors identified, the diketo acids and the pyranodipirimidines and will discuss antiviral resistance development against these drugs.
NOVEL ANTIVIRAL TARGETS DURING RETRO-VIRAL INTEGRATION
HIV-1 integration is a complex process that starts with a partially synthesised cDNA in the cytoplasm and ends with proviral DNA inserted in a transcriptional active region of the chromosome. Although integrase by itself can carry out the basic biochemical reactions in vitro, other viral and cellular proteins play important roles in the integration process. All steps represent potential targets for therapeutic intervention. Although inhibition of host factors could be associated with cellular toxicity, this can be overcome if integration of HIV can be prevented at a concentration that is not toxic for the cells. New assays have to be developed to detect inhibition of the interaction of viral and cellular factors. The following targets could be envisaged. (1) The final stages of reverse transcription and the first steps of integration are concurrent, and a physical and functional interaction between RT and IN has been described [24, 81, 90] . (2) A specific integrase-DNA complex is formed, possibly emerging from the reverse transcription process. Integrase-DNA interaction in vitro has recently been characterised with Fluorescence correlation spectroscopy [86] . Many integrase inhibitors interfere with integrase-DNA binding in vitro, but for most compounds inhibition of integration in cell culture has not been demonstrated, Pyranodipyrimidines were shown to inhibit this step and thus represent the prototypical Integrase Binding Inhibitors (INBI's) [66] . (3) Multimerization of IN, which is induced upon binding of integrase to DNA [86] and is required for enzymatic activity, may be targeted by transdominant negative integrase mutants, that could be provided by gene therapy. Peptides targeting the dimer interface and inhibiting 3' processing in the test tube have been reported [96] . (4) The endonucleolytic 3'-processing reaction is followed by (5) the juxtaposition of both LTR ends within the PIC to ensure transport through the nucleopore and the concerted integration of both LTR ends. The cellular co-factors, Barrier to Auto-Integration factor (BAF) and/or High Mobility Group Protein I (Y) (HMGI(Y) are likely involved in shaping the right architecture of the PIC. (6) The cleaved viral DNA within the PIC is actively transported through the nucleopore into the nucleus. Many protein and DNA determinants have been described that act synergistically [69] . Because of this redundancy, it is not clear whether inhibition of one determinant will be sufficient to block the import. (7) After nuclear import the complex will be directed to the chromosomes where the integration site is selected. An elegant and recent study by Schröder et al. unambiguously demonstrated that active genes are strongly favored as integration sites for HIV-1 [79] . However, the mechanism of integration site selection has to be unraveled before specific inhibitors can be identified. Integrase interactor I (Ini1) has been postulated to target the proviral DNA into actively transcribed regions [43] . Alternatively, transcriptional activation may be induced by integration. The recently identified integrase-binding partner, Lens EpitheliumDerived Growth Factor (LEDGF), a known transcription factor, may well provide the missing link between lentiviral integration and transcription [16, 56] . (8) The DNA strand transfer step is a valid antiviral target, as shown by the inhibition of viral replication by diketo acids [41] . This class of inhibitors is referred to as integrase Strand Transfer Inhibitors (INSTI's). (9) In an unproductive pathway of integration, DNA circles are formed. It has recently been shown that Ku, a cellular protein involved in nonhomologous end joining, is required for this step [53] . Inhibition of DNA strand transfer by diketo acids leads to an increase in 2-LTR circles. Although 2-LTR circles are diluted upon cell division [11, 68] , their fate and potential pathogenic role in non-dividing cells such as macrophages is not clear. (10) Integration is completed by DNA repair, probably carried out by cellular DNA repair enzymes. It will be difficult to obtain selective inhibitors of DNA repair.
Cellular Cofactors of Integration as Potential Antiviral Targets
The retro-transcribed viral DNA is associated with a dense nucleoprotein complex derived from the virion core. This nucleoprotein complex is called the pre-integration complex (PIC) and is competent to insert endogenous cDNA into a target DNA supplied in vitro [23, 29] . Functional HIV-1 PICs were found to contain integrase, reverse transcriptase, matrix protein p17 and small amounts of capsid protein p24 [8, 58] . Viral DNA is compacted to fit in the PIC. Since the sites of HIV cDNA integration in each target DNA are always separated by a defined 5 bp distance, it seems likely that the cDNA ends are held together by proteins. Although some co-factors have been identified, but their respective roles and mechanism are less well understood. The yeast two-hybrid system was used to isolate a cellular binding partner for HIV-1 IN [42, 43] . Ini1 has amino acid similarity with the yeast transcriptional activator SNF5, a component of the multiprotein SWI/SNF complex [88] . Because Ini1 directly interacts with HIV IN and is involved in chromatin remodelling, it was put forward that Ini1 might target the retroviral integration machinery to open chromatin regions. The minimal integrase interacting binding domain has been characterised, as well as the minimal domain responsible for the binding to DNA [59] . Ini1, however, was not detected in the pre-integration complex. Recently, it has been claimed that Ini1 is specifically incorporated into HIV-1 virions and that expression of a cytoplasmically located fragment of Ini1 potently inhibited HIV-1 particle production and replication in a transdominant manner, suggesting a role during late events of the viral life cycle [93] . In contrast, incoming retroviral PICs were shown to trigger the exportin-mediated cytoplasmic export of Ini1, implying a role during early steps of HIV replication. These paradoxical data await full explanation [82] .
While developing methods to purify PICs from freshly infected cells, Farnet and Bushman [28] identified HMGI(Y) as a factor important for integration in vitro. This is a nonhistone chromosomal protein important for transcriptional control and chromosomal architecture. Addition of HMGI(Y) (or Ini1) stimulates in vitro integration reactions with recombinant integrase [28, 43] . However, the function of each host factor during in vivo integration remains to be determined.
In in vitro PIC integration assays, there is a strong preference for intermolecular integration, instead of intramolecular integration. Lee and Craigie [51] were able to identify the barrier to auto-integration factor (BAF), a polypeptide of 89 amino acids. BAF was able to restore the integration activity of salt-stripped PICs at nanomolar concentrations, whereas for HMGI(Y) micromolar concentrations were required [13] . BAF is a highly evolutionarily conserved DNA binding protein and its structure has been resolved by NMR [12] . BAF is largely helical and each subunit is composed of five helices. Recently, the crystal structure of homodimeric BAF was resolved at a 1.9 Å resolution [83] , and it was determined that the fold of the BAF monomer resembles that of the second domain of RuvA. This comparison revealed the presence of the helix-hairpin-helix non-specific DNA binding motif within BAF. The presence of this DNA binding motif explains how BAF could bridge dsDNA both intra-as well as intermolecularly.
Cherepanov et al. [16] isolated HIV-1 integrase (IN) complexes derived from nuclei of human cells stably expressing the viral protein from a synthetic gene [15] . In those nuclear extracts IN was present as part of a large distinct complex composed of IN tetramers associated with a cellular protein with an apparent molecular weight of 76 kDa. This novel integrase interacting protein was found to be identical to LEDGF/p75, a protein implicated in regulation of gene expression and cellular stress response [16] . Maertens et al. [56] showed that both the N-terminal zinc binding domain and the central core domains of IN are involved in the interaction with LEDGF/p75. Both domains are essential for nuclear localisation of IN. In contrast to LEDGF/p75, its alternative splice variant, p52, did not interact with HIV-1 IN in vitro and in living cells. Finally, RNA interference-mediated knockdown of endogenous LEDGF/p75 expression abolished nuclear/chromosomal localisation of IN. Maertens et al. [56] concluded that the interaction with LEDGF/p75 accounts for the karyophilic properties and chromosomal targeting of HIV-1 IN. Current research addresses the functionality of LEDGF during integration and attempts to validate LEDGF as new antiviral target.
TECHNOLOGIES TO CORROBORATE INTEG-RASE AS ANTIVIRAL TARGET

Oligonucleotide-based Integrase Assays used to Identify Integrase Inhibitors
The use of synthetic oligonucleotides that represent the terminal sequences of the viral DNA, and recombinant HIV-1 integrase, expressed in E. coli, has led to an in vitro test system for integration [80, 18, 9, 45] . The assay proved to be useful to investigate in detail the reactions catalyzed by the enzyme (for a schematic representation of the in vitro integration assay, see Fig. 2 ). In vitro, an apparent reversal of the strand transfer joining reaction called disintegration, can be catalyzed by the core domain of integrase. Disintegration has not been shown to occur in vivo. The in vitro assays have been reviewed recently [22] .
The Use of PIC in an Integration Assay
PICs can be partially purified from cells infected with HIV-1 and used as a source of integrase activity in vitro [7, 23, 29] . PICs can direct joining of both ends of the viral cDNA in a coordinated fashion yielding a product resembling the gapped integration intermediate. Many of the inhibitors that were found using the oligonucleotide assay and recombinant integrase proved inactive in the PIC assays [27, 30] . PIC assays have not been widely used due to technical difficulties in handling large amounts of infectious HIV. Recently, a PIC integration assay was developed using DNA-coated microtiter plates that speeds up in vitro assaying of PIC integration [39] . In a PIC integration assay developed by Brooun et al. [5] , the integration events are directly detected and quantified using a real-time PCR amplification. This assay consists of 3 steps performed in a single tube and yields quantitative data within 4-5 hr.
PCR-based Quantification of HIV DNA Species During Replication
Quantitative, real-time PCR techniques have been developed that allow quantification of the various HIV DNA species during HIV infection by selecting specific primer/probe combinations [10] . HIV-1 derived vectors are used to ensure single-round infection, although differences may exist between kinetics of HIV infection and HIV vector transduction [85] . A first Quantitative-PCR (Q-PCR) quantifies total HIV DNA. During the first hours of the replication cycle, the amount of total HIV DNA is the result of the ongoing reverse transcription. After multiple passaging, total HIV DNA will reflect integration, although DNA circles may confound this analysis. The 2-LTR circles can be quantified directly by a specific primer pair detecting the LTR linkage. Integrated proviral DNA is quantified by Alu-PCR. Alu-repeats are defined as short interspersed nuclear elements (SINE) of approximately 300 bp and occupy approximately 5 % of the human genome. On average, an Alu-repeat is present every 5000 bp. Using one Alu-repeat and one HIV-1 specific primer, one is able to PCR-amplify a fraction of integrated proviral DNA. A standard is obtained by measuring integrated DNA present in transduced and passaged cells with the Q-PCR for total DNA. The signal obtained by Q-Alu PCR on this DNA standard can then be attributed to a defined amount of integrated DNA. This technology, theoretically, allows identification of the antiviral target in cell culture. However, in its current version, the assay is labour-intensive, timeconsuming and expensive. The sensitivity of the Alu-PCR is poor, since integrants too far away from an Alu-repeat will not be amplified. Therefore, technological improvements of this methodology will be required. The 2-step PCR amplification, described by O'Doherty et al. [64] , already proved to be 10 to 100 times more sensitive than the previously reported Q-Alu-PCR for the quantification of HIV integration. This 2-step PCR consists of a non kinetic preamplification step, performed with primers that anneal at genomic Alu elements and HIV-1 gag sequences, and is followed by a kinetic Q-PCR that quantitates the HIV-1 LTR sequences [64] . An alternative PCR assay to quantify HIV integration in cell culture has been described [84] . Integrated HIV DNA is detected by a nested Alu-PCR; extrachromosomal HIV DNA is amplified in parallel. In this assay PCR products are analysed by Southern hybridisation. The LTR circles, as such, are not detected. However, quantification by classical PCR is less accurate than when using real-time PCR.
Quantification of total HIV DNA, 2-LTR DNA circles and integrated proviral DNA (through Alu-PCR) during HIV infection, provides a direct way to discriminate between RT and IN inhibitors [10] . In the presence of an RT inhibitor (AZT), total HIV DNA synthesis, 2-LTR circle formation and proviral DNA integration are inhibited. Inhibition of DNA strand transfer by authentic IN inhibitors such as the diketo acid L-708,906, results in an increase in 2-LTR circles, an inhibition of proviral DNA formation but no effect on DNA synthesis by reverse transcription (Fig. 3). 
DNA-induced Polymerization of HIV-1 Integrase Analyzed with Fluorescence Fluctuation Spectroscopy
Vercammen et al. [86] have studied the association of integrase to fluorescently labelled oligonucleotides using fluorescence correlation spectroscopy (FCS) and the inhibition by INBI's. The binding of integrase to the fluorescent oligonucleotides resulted in the appearance of bright spikes during fluorescence correlation spectroscopy measurements. These spikes reflect the formation of high molecular mass protein-DNA complexes (Fig. 4) . The   Fig. (2) . Analysis of the integration reaction using radiolabeled oligonucleotides. A schematic representation (left panel) and an autoradiogram (right panel) of the integrase-mediated reactions is presented. A 20-base pair oligonucleotide substrate, consisting of the terminal U5 LTR sequence is used to evaluate the integrase-mediated reactions. In this experiment, inhibition of the overall integration by a dilution series of compound X and Y was evaluated. The 3'-processing reaction cleaves off the terminal GT dinucleotide (formation of the -2 band, black arrow) and this cleaved substrate will be covalently inserted into another DNA oligonucleotide in the strand transfer reaction (higher bands, grey arrow).
•:
32 P, radioactive label.
fluorescence of the free DNA can be separated from that of the spikes using a statistical method. From the decrease of the concentration of free oligonucleotides, the association constant can be determined. The formation of the fluorescent protein-DNA complex was inhibited by guanosine quartets, and the inhibition constant was determined at 1.8 ± 0.6 x 10 8 m -1 . Displacement of bound DNA with G-quartets allowed the determination of the dissociation rate constant and proved the reversibility of the association process. Using this method, PDP has been shown to inhibit the interaction between IN and DNA as well. Current research focusses on the interaction of LEDGF with HIV-1 integrase in vitro using FCS. 
Chimeric Virus Technology
Selection of drug-resistant HIV strains in cell culture followed by sequencing of viral genes is an important approach to identify the antiviral target of a particular drug. In the case of G-quartets and L-chicoric acid, the absence of mutations in the integrase gene but presence of mutations in gp120 of virus strains selected until resistant in cell culture, convinced us that integration was not the primary antiviral target [26, 70] . Full proof is provided by recovery of resistance after recombination of the gene carrying the mutations in a wild type background. We have designed Chimeric Virus Technology that allows the generation of viable virus by homologous recombination of a PCRamplified selected strain-derived IN gene into a proviral wild-type HIV-1(NL4.3) clone that has been deleted for the corresponding IN-gene [32] . We have selected drug-resistant strains in the presence of the diketo acid L-708,906 [33] . By introducing the IN gene of this selected strain into the wild type background, the resistance phenotype of the originally selected strain was completely recovered. Although resistance selection and recombination together provide full proof of the antiviral target, the approach is not always feasible. To select resistance, a gradual increase in drug concentration during cell culture is required. For drugs with poor solubility and/or low selectivity indices (SI), as is often the case with initial lead compounds, selection of drug resistance will not always be possible. Lead optimisation by chemical modifications may be required to develop a compound with a selectivity index that is sufficiently high for resistance selection. 
HIV INTEGRASE INHIBITORS
Many characteristics of the biochemistry and the molecular biology of integration render it a process difficult to target effectively with classical drugs. In sharp contrast to reverse transcriptase that is catalysing a polymerisation reaction, 3' processing and DNA strand transfer reactions are carried out only once at each LTR-end during the normal retroviral replication cycle. Integrase inhibition is thus an allor-none event. However, the identification of the diketo acids as authentic inhibitors of DNA strand transfer has provided a proof-of-principle that true inhibitors of integration, acting in cell culture, can be identified [41] .
The catalytic activities leading to integration take place in a DNA-protein complex, the pre-integration complex. Steric hindrance may limit accessibility of drugs to the catalytic sites. In this complex, integrase is tightly associated with the processed DNA substrate. There might be a short window, early after infection, where formation of the integrase-DNA association could be prevented. Unfortunately, the negatively charged inhibitors that interfere with IN-DNA complex formation, such as G-quartets, do not enter cells. PDP, however, do inhibit HIV replication by interference with IN-DNA complex formation [66] .
Cell culture based assays have been developed with cell lines and laboratory strains that facilitate HIV replication. It is not clear, whether inhibition of integration is assayed at best under these artificial culture conditions. In the oligonucleotide-based enzymatic tests not all steps of the integration process are assayed for and the inhibitors discovered may target biochemical interactions (e.g. Mg chelation) shared by many other enzymes, which would make it difficult, if not impossible, to dissociate activity and toxicity of the compounds. Therefore, new assays should be developed that allow identification of authentic integrase inhibitors and search for the additional subtargets during the integration process.
The lack of three-dimensional structure of full-length integrase impedes the structure-based design of integrase inhibitors. Because of the known conformational changes in integrase induced upon DNA binding [25] , co-crystallisation of integrase with a model DNA substrate should be required.
Integrase Inhibitors with Multiple Mode of Anti-HIV Action
A vast series of compounds have been reported to inhibit the integrase activity in oligonucleotide assays [73, 74] (Fig.  5) but so far only the diketo acids [41] and the pyranodipyrimidines (PDP) [66] have been proven to inhibit viral replication by interference with the integration step. Most integrase inhibitors do not show antiviral activity or are too toxic in cell culture. Moreover, for two classes of integrase inhibitors with antiviral activity, our group has demonstrated that viral entry and not integration, is the predominant antiviral target in cell culture.
G-quartets
G-quartets are oligonucleotides that can form a highly stable intramolecular four-stranded DNA structure containing two stacked guanosine-quartets (G-quartets) [65] .
The prototypical AR177 (Zintevir), a 17-mer composed of deoxyguanosine and deoxythymidine residues [76] , is a potent inhibitor of HIV replication in cell culture [65] . Although G-quartets inhibit HIV IN activity in the nanomolar range [14, 57] , we have clearly shown by selecting and sequencing drug-resistant HIV-1 strains that the antiviral activity in cell culture is due to the inhibition of viral entry rather than integration [14, 26] .
L-chicoric Acid
The dicaffeoyl quinic acid and L-chicoric acid (L-CA) derivatives (Fig. 5) inhibit HIV-1 IN in vitro and HIV-1 replication in cell culture [77, 78] . An HIV-1 strain resistant to L-chicoric acid was selected, and the resistance mutation was mapped in the IN gene (G140S) [47] . An HIV-1 strain selected for resistance against L-CA in our laboratoryacquired mutations in the viral envelope glycoprotein gp120, but not in the integrase gene [71] . In addition, recombinant virus that carried the env gene of the resistant strain was resistant to L-CA.
Integrase Inhibitors with Proven Anti-integrase Activity in Cell Culture
The diketo acids (DKA) represent the first family of IN inhibitors reported [41] . Antiviral activity in cell culture as a consequence of a specific inhibition of the DNA strand transfer step of the integration process was clearly demonstrated. Because of their specific mechanism of action, DKA are referred to as integrase strand transfer inhibitors (INSTIs). The diketo derivative 5-CITEP was cocrystallised with the HIV-1 integrase core domain [36] . It has been demonstrated that diketo acids only bind to integrase after the enzyme has bound to target DNA [25] . Therefore, the relevance of the co-crystal model should be questioned because no target DNA was present at the time of crystallisation.
The diketo acid L-708,906 showed activity against various HIV-1, HIV-2 and SIV strains at micromolar concentrations [40, 72] . A series of heterocyclic analogues in the class of diketo compounds that are metabolically more stable, due to the replacement of the 1,3-diketo acid moiety into 8-hydroxy- [1, 6] Shionogi & Co Ltd replaced the carboxylic acid group of DKA with isosteric moieties, such as a tetrazole or a triazole group. S-1360, a structural analogue of the diketo acids was selected for further study from more than 300 compounds produced under this program. S-1360 was the first integrase inhibitor to reach clinical studies and is currently under development by Shionogi-GlaxoSmithKline Pharmaceuticals. This low molecular weight compound inhibits IN in the nanomolar and viral replication in the micromolar range. S-1360, which is orally bioavailable has been subject of a phase I study in HIV negative volunteers. The results of this study indicated that S-1360 was generally well tolerated active against virus strains that were resistant towards inhibitors of viral entry or reverse transcription. In enzymatic assays, PDPs inhibited both reverse transcription and integration reactions. For the active congeners a correlation was found between the inhibitory activity in cell culture and the inhibitory potency on the integrase reactions. V-165 was the most potent derivative. In Time-Of-Addition (TOA) experiments V-165 appeared to interfere with the viral replication cycle at a moment following reverse transcription. To discriminate between reverse transcription and integration as the major antiviral target in cell culture, a series of quantitative PCRs was carried out on DNA extracted from cells transduced with HIV-1 vectors in the absence or presence of V-165. In the presence of V-165 there was no inhibition of total DNA synthesis, a small increase in 2-LTR circle formation and a clear inhibition of integration. The diketo acid L-708,906 showed a similar profile, although the increase in 2-LTR circles was more pronounced. Possibly, this relates to the inhibitory effect of V-165 on the DNA-integrase complex formation that takes place in the cytoplasm of the infected cell and may be required for efficient nuclear import.
VIRAL RESISTANCE AGAINST INTEGRASE INHIBITORS
Since the diketo derivative S-1360 entered into a clinical trial in HIV seropositive individuals [90] Table 2) . We have independently selected HIV-1(III B ) strains in the presence of increasing concentrations of the diketo acid L-708,906 (III B /L-708,906) and analysed the selected strains genotypically and phenotypically at different stages throughout the selection process [33] . An accumulation of the mutations T66I, L74M and S230R was observed during the selection (Fig. 6 and Table 2 ). After 35, 40 or 60 passages respectively, the mutations T66I, T66I/L74M or T66I/L74M/S230R were detected in the total virus population. Amino acids at positions 66 and 74 are in close proximity to the active site, and position 230 is located in the DNA-binding domain of IN (Fig. 6) .
Phenotypic data confirmed that the selected strains were indeed drug-resistant. The double mutant, selected after 40 passages, was 4-fold less susceptible to L-708,906 than the wild-type (WT) strain, while the triple mutant showed a more than 10-fold decrease in susceptibility to L-708,906. Of interest, cross-resistance (>6-fold) towards the integrase inhibitor S-1360 was already observed for the single mutant (T66I). All viral mutants remained fully susceptible to inhibition by V-165 and inhibitors interfering with RT, protease or viral entry [33] . As reported by Hazuda et al., the individual mutations T66I, S153Y or M154I in IN conferred an up to 4-and 7-fold loss of susceptibility to L-708,906 and L-731,988, respectively, whereas increased resistance (>20-fold) was achieved when the mutation T66I was combined with S153Y or M154I, as observed in the L-708,906-selected population [41] .
To assess the significance of the observed mutations for the resistance profile of the selected strains, a recombination assay, termed Chimeric Virus Technology (CVT) for the HIV-1 IN-gene was established. Using IN-CVT, the mutant IN genes of the selected strains are cloned into the background genome of a WT laboratory strain. The resulting recombined strains displayed the same loss in sensitivity to the IN inhibitors as the parental in vitro selected strains, indicating that the mutations in the recombined region are responsible for the cross-resistance phenotype of the selected strains. Viral fitness experiments designate substantially reduced replication fitness of the mutant strains in comparison to wild-type HIV-1(III B ) as a result of the druginduced mutations in integrase. The decreasing order of replication fitness of viral mutants was the following: T66I > T66I/L74M/S230R > T66I/L74M, pointing to a positive role for S230R in the replication ability of the triple mutant virus [33] .
In addition, mutant IN enzymes were generated in order to evaluate the effect of the different mutations on enzymatic activity and drug sensitivity in the oligonucleotide-based assay.
IN mutants containing T66I/L74M and T66I/L74M/S230R displayed impaired 3'-processing and strand transfer activities (up to 5-fold). A comparable attenuation of viral growth and integrase enzymatic activity was reported for the integrase mutation G140 (associated with antiviral resistance against chicoric acid) [48] and the mutations T66I combined with S153Y or M154I, while the individual mutations T66I, S153Y or M154I did not appear to impair catalytic activity or infectivity [41] . In the overall integration reaction, L-708,906 and S-1360 inhibited the enzyme containing T66I/L74M/S230R to a 2-to 4-fold lower extent than WT IN, whereas no significant loss in susceptibility to these compounds was observed for the T66I and T66I/L74M mutants. Full activity against the T66I/L74M/S230R enzyme was observed for V-165 [33] . The single mutations T66I, S153Y or M154I in IN result in up to 6-fold loss of susceptibility to L-708,906 and L-731,988, whereas increased resistance (>15-fold) was reached when the mutation T66I occurred in combination with S153Y or M154I in the enzyme [41] .
Interestingly, in our hands the extent of resistance caused by the mutations towards L-708,906 and S-1360 in cell culture (at least 5-fold) could not be entirely reproduced at the enzymatic level (2-fold resistance). A possible explanation for this observation could be related to the artificial nature of the oligonucleotide-based assay. The isolated enzymatic assay does not account for concerted integration of both LTR ends or other functionalities of HIV integrase, such as nuclear import or interaction with cellular co-factors. King et al. [48] obtained an analogous divergence in the extent of resistance in cell culture versus enzymatic assay. They observed only a modest decrease in sensitivity of the recombinant integrase G140S mutant towards chicoric acid and DKA compared to the loss in susceptibility of the mutant virus [47] . However, the resistance towards DKA observed by Hazuda et al. [41] was approximately 3-fold more pronounced in their enzymatic assay than in their cellular assay for their different observed mutants. The discrepancy between these results may be explained by the fact that the inhibitory effect of DKA in the latter study has been assessed using an oligonucleotide-based assay that measures DNA strand transfer specifically. In conclusion, cell culture and enzymatic data from both our group and Hazuda's group indicate that more than one mutation is required for reduced sensitivity to L-708,906 [33, 41] . The mutation T66I was sufficient to cause resistance to S-1360 in cell culture, although reduced susceptibility in the enzymatic assay required the mutations T66I/L74M/S230R [33] . The observation that resistance against diketo acids in cell culture does emerge after a relatively short time period is of clinical significance. From a clinical point of view, HIV strains resistant towards L-708,906 display cross-resistance to the diketo derivative S-1360. Of interest in this context is the noteworthy reduction in viral fitness associated with the emergence of the observed mutations. Given that the DKA-resistant strain remained sensitive to inhibition by V-165, it is apparent that INBI's and INSTI's have distinct antiviral resistance profiles.
CONCLUSIONS
After more than a decade of an intensive search for inhibitors of HIV integrase, to date only two classes of authentic integrase inhibitors has been identified, the diketo acids [41] and the pyranodipirimidines [66] . DKA provided the proof-of-principle that integrase inhibitors can block viral replication and that. lentiviral DNA integration thus can be considered as a bona fide antiviral target. The elucidation of a co-crystal of full length IN complexed with DNA, the development of an efficient and selective system for the evaluation of integrase inhibitors in cell culture as well as the clarification of the exact role of host co-factors during integration, will facilitate the development of new integrase inhibitors. For the moment, we have to rely on a combination of experimental approaches to prove the authenticity of integrase inhibition in cell culture. Authenticity of integrase inhibition and avoidance of mistaken identity is a prerequisite for delineating the appropriate structure-activity relationship, which in turn, is a prerequisite for identifying the appropriate lead compound for clinical development. Now that integrase inhibitors are entering clinical trials, resistance development in patients should carefully be monitored. Pre-clinical studies point to sequential accumulation of drug-induced mutations, cross-resistance between INSTI's but lack of cross-resistance with INBI's. 
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